Cytek Biosciences Inc (CTKB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cytek Biosciences Inc stock (CTKB) is currently trading at $4.63. Cytek Biosciences Inc PS ratio (Price-to-Sales) is 2.86. Analyst consensus price target for CTKB is $6.00. WallStSmart rates CTKB as Sell.
- CTKB PE ratio analysis and historical PE chart
- CTKB PS ratio (Price-to-Sales) history and trend
- CTKB intrinsic value — DCF, Graham Number, EPV models
- CTKB stock price prediction 2025 2026 2027 2028 2029 2030
- CTKB fair value vs current price
- CTKB insider transactions and insider buying
- Is CTKB undervalued or overvalued?
- Cytek Biosciences Inc financial analysis — revenue, earnings, cash flow
- CTKB Piotroski F-Score and Altman Z-Score
- CTKB analyst price target and Smart Rating
Cytek Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cytek Biosciences Inc (CTKB) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, eps growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Cytek Biosciences Inc (CTKB) Key Strengths (3)
Earnings per share surging 73.50% year-over-year
Trading at 1.69x book value, attractively priced
64.87% held by institutions, strong professional interest
Supporting Valuation Data
Cytek Biosciences Inc (CTKB) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Modest revenue growth at 8.10%
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.86x sales
Supporting Valuation Data
Cytek Biosciences Inc (CTKB) Detailed Analysis Report
Overall Assessment
This company scores 41/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.69) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 73.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.86) suggest expensive pricing. Growth concerns include Revenue Growth at 8.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -18.00%, Operating Margin at -9.00%, Profit Margin at -33.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -18.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CTKB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CTKB's Price-to-Sales ratio of 2.86x trades at a deep discount to its historical average of 7.98x (24th percentile). The current valuation is 91% below its historical high of 33.21x set in Sep 2021, and 61% above its historical low of 1.77x in May 2025. Over the past 12 months, the PS ratio has expanded from ~2.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cytek Biosciences Inc (CTKB) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Cytek Biosciences Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 201M with 8% growth year-over-year. The company is currently unprofitable, posting a -33.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.09 indicates a conservative balance sheet with 93M in cash.
The company is unprofitable with a -33.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Cytek Biosciences Inc.
Bottom Line
Cytek Biosciences Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(66 last 3 months)
| Insider | Type | Shares |
|---|---|---|
YAN, MING Director, CHIEF TECHNOLOGY OFFICER | Sell | -1,176,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:21:53 AM
About Cytek Biosciences Inc(CTKB)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, providing state-of-the-art cell analysis solutions to the life sciences industry. The company's advanced technologies facilitate comprehensive cellular analyses that are crucial for research in immunology, cancer diagnostics, and drug development. With a commitment to innovation and excellence in customer service, Cytek has solidified its status as a key contributor in the biotechnology sector, addressing the growing need for precise cell analysis tools. Boasting a diverse product portfolio and a robust market position, the company continues to drive advancements in the rapidly evolving field of cell biology research.